Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Alterity Therapeutics Ltd., a biotech company focused on neurodegenerative disease treatments, has filed its Annual Report for 2024, which includes audited financial statements, with the SEC and made it accessible on their website. Shareholders can request a free hard copy of the report. The company’s key drug, ATH434, is under Phase 2 trials for Parkinsonian disorders, highlighting Alterity’s commitment to addressing neurological diseases.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.
